DATscan and SPECT imaging ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00129181 (ClinicalTrials.gov) | January 2005 | 9/8/2005 | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease | A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease | Parkinson Disease;Parkinsonian Syndrome | Drug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imaging | Institute for Neurodegenerative Disorders | Pfizer;GE Healthcare | Completed | 40 Years | N/A | Both | 30 | N/A | Austria;Germany;Italy;Spain;United Kingdom |